Bank of America upgraded Dentsply Sirona (XRAY) from Neutral to Buy and raised its price target from $13 to $17, calling the dental equipment maker a compelling risk-reward opportunity at current levels. BofA analyst Allen Lutz set the $17 target at 15x estimated 2026 EPS of $1.15, arguing that even modest execution could drive meaningful multiple expansion. The stock was trading near $12.68 as of March 10 — roughly 34% below BofA's target — after losing more than 75% of its value from its 2021 peak above $65. The upgrade comes weeks after Dentsply renewed its critical U.S. distribution partnership with Patterson Dental, securing continued access to Patterson's practice customer base for its CEREC, Primescan, and Axeos product lines.

Dentsply's fall from grace has been one of the dental industry's most dramatic stories. Once the dominant dental equipment manufacturer with a $15 billion market cap, the company has been battered by an SEC investigation, leadership turnover, and a prolonged slump in dental equipment spending. The stock now trades at a fraction of its former valuation. But BofA's thesis is straightforward: at $12.68, the market is pricing in near-permanent impairment, and even a modest return to normalized earnings would justify significant upside. The company also gained FDA clearance for the first-ever dental-dedicated MRI system, a potential category creator in diagnostic imaging.

For dental practices, Dentsply's trajectory matters because it is one of only a handful of companies that manufactures the core digital workflow — scanners, milling units, imaging systems — that modern practices depend on. The Patterson distribution renewal ensures equipment availability and service support, a concern that had lingered as Dentsply's financial troubles mounted. BofA did caution that upcoming earnings could bring volatility: management may cut the dividend, increase investment spending, and issue guidance below Street expectations. But the analyst framed these potential negatives as short-term pain that would create long-term value.

Watch for Dentsply's next earnings report for clarity on whether management will indeed sacrifice near-term returns for a turnaround investment cycle. The dental MRI approval is a potential wildcard — if it gains clinical traction, it could open an entirely new revenue stream in a $3 billion+ dental imaging market. Also monitor whether other analysts follow BofA's lead: the consensus price target sits at $14.67, meaning the Street remains cautious even as BofA takes a more aggressive stance. Insider purchases — including a 5,000-share buy by director James Forbes on March 9 — add a modestly bullish signal.